Introduction
Although examinations, surgery, and chemotherapy are continuously improving, the 5-year survival rate of osteosarcoma is still below 60%. 1 Osteosarcoma usually has a complex genome mutation, which was proven by many studies at the molecular level. 2 Molecular target therapy is a particularly effective method for the treatment of recurrent cancer. Epidermal growth factor receptor (EGFR) is one of 4 members of the HER family of receptor tyrosine kinases. 3 As EGFR can activate many signaling cascades, such as the PI3K/Akt, and Jak/STAT pathways, it plays an important role in the regulation of cell proliferation, survival, and metastasis.
MicroRNA (miRNA) is the key regulator of gene expression in many species. More than 60% of human protein coding genes are downregulated by miRNAs. 4 It has been reported that the expression of miRNA in osteosarcoma is abnormal. 5 Studies have miR-135b can target c-Myc in osteosarcoma and suppress the occurrence and development of cancer. 8 miR-143 can suppress osteosarcoma metastasis by regulating matrix metalloproteinase (MMP)-13 expression in vitro. 9 All of these data proved that miRNA plays a very important role in the development of osteosarcoma. miRNA may be a therapeutic target in the treatment of osteosarcoma.
miR-141-3p has been reported to inhibit the occurrence and development of many kinds of tumors. 10 It can suppress the migration and invasion of HCC cells. 11 However, there have been no reports on the expression and function of miR-141-3p in osteosarcoma.
In this study, we examined the expression of miR-141-3p and EGFR in osteosarcoma and analyzed the correlation between them. It was found that miR-141-3p can inhibit the growth of osteosarcoma cells by regulating the expression of the EGFR protein.
Materials and methods

Patients and tissue samples
Thirty-two patients with primary osteosarcoma hospitalized in Shengjing Hospital between 2010 and 2015 were retrospectively analyzed. All patient information is shown in Table 1 . The treatment details were as previously described. 12 All patients reviewed the methods and significance of the study and provided written informed consent. The project was approved by the ethics committee for medical science research of Shengjing Hospital (R20110711). All osteosarcoma tissues were pathologically confirmed to be osteosarcoma. Before obtaining the tissue, the patient had not undergone any chemotherapy, radiotherapy, or tumor-related drug therapy.
Western blot analyses
To determine the expression of protein in tissues and cells, Western blot was used; whole cell extracts (lysate) were prepared from 1×10 6 cells or tissues in lysis buffer. Approximately 60 µg of the protein was resolved on 10% sodium dodecyl sulfate-polyacrylamide gels. After electrophoresis, the proteins were electrotransferred to nitrocellulose filters, and the membrane (Amersham, Shanghai, China) was blocked with 5% nonfat dry milk in tris-buffered saline with Tween 20 for 1 hour at room temperature and incubated with primary antibody. Target proteins were probed with specific antibodies -EGFR (1:1,000), Akt (1:1,000), Akt p-Ser473 (1:1,000), cyclin D1 (1:1,000), bcl-2 (1:1,000), bax (1:1,000), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (1:3,000) and horseradish peroxidase-rabbit secondary antibody (1:5,000) (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). To ensure equal loading, gels were stripped and reprobed with antibodies against GAPDH. All polyvinylidene difluoride membranes were detected by enhanced chemiluminescence (Pierce Technology, Beijing, China).
real-time polymerase chain reaction (rT-Pcr)
RT-PCR was used to detect the expression of mRNA in tissues and cells. Total RNA was extracted from tissues and MG63 cells by TRIzol (Thermo Fisher Scientific, Waltham, MA, USA) which was used to overhang cells or homogenate tissue. Add chloroform to mix and centrifuge and leave the supernatant. Add isopropanol and remove the supernatant by centrifugation. RNA was obtained after the use of ethanol to clean. The expression of miR-141-3p was detected with a Stem-Loop RT-PCR assay as previously reported. 13, 14 Primer sequences were synthesized as shown in Table 2 .
All the reactions were carried out as described previously. 15 
immunohistochemical staining
Immunohistochemical staining was used to detect the expression of EGFR in tissues. All osteosarcoma patients fulfilled the diagnostic criteria for osteosarcoma as defined in the World Health Organization classification. We used grade, tumor, metastasis (GTM) classification to evaluate osteosarcoma. G refers to the benign and malignant degree of the tumor. T refers to the range of tumor invasion. M refers to regional or distant metastasis. Tissues were fixed with 4% paraformaldehyde, permeabilized for 10 minutes with PBS containing 0.1% Triton X-100 and blocked with 1% bovine serum albumin. Immunostaining was performed 
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effect of overexpression of mir-141-3p on osteosarcoma using the appropriate primary (EGFR, 1:800) and secondary antibodies, and images were acquired using an Olympus fluorescence microscope. Immunohistochemical results were judged by HSCORE (histological score). 16 Immunostaining intensity was estimated for each tissue core as follows: 1, weak; 2, moderate; or 3, strong.
survival function
We use the Kaplan-Meier method to compute survival function. The abscissa is the survival time. The ordinate is the size of the survival function. Patients with a high expression of miR-141-3p in osteosarcoma tissues.
Dual luciferase reporter assay
Dual luciferase reporter assay was used to detect whether there is a direct binding site between miR-141-3p and EGFR. The EGFR 3′ untranslated region (3′-UTR) was PCR amplified and cloned into the pMIR-REPORT™ vector (Ambion, Shanghai, China). The primers were as follows: EGFR-WT, F: 5′-CGAATGGGCCTAAGATCCCG-3′, R: 5′-CGGUCGUCUCGUCAGUC-3′, EGFR-DEL (Mutation of the loci of EGFR and miR-141-3p), F: 5′-CGA ATGGGCCTAAGATCCCG-3′, R: 5′-CUCGGAGAG GGAC-3′. pMIR-REPORT™-β GAL (control), miR-141-3p mimic and miR-141-3p antisense (AS) with EGFR-WT or EGFR-DEL were introduced into MG63 and HOS cells. After 36 hours, the luciferase activity was measured using the Dual Luciferase Reporter Assay System (Promega, Beijing, China) as described. 17 
cell count
Cell count was used to detect the effect of miR-141-3p on cell proliferation. The cell count was also used to determine the quantity of cells after transfection with 0, 50, and 100 nm miR-141-3p mimic/inhibitor using a Malassez counting chamber. Cells were trypsinized from 6-well plates, and cells from each well were counted 3 times.
MTT assays
hFOB1.19 cells and human osteosarcoma cell lines HOS and MG-63 were obtained from the American Type Culture Collection (Manassas, VA, USA). MTT assay was used to detect the effect of miR-141-3p on cell proliferation. Cells were seeded in 96-well plates; 2,000 cells in 200 µL of media in each well and incubated overnight at 37°C in a humidified 5% CO 2 incubator. On the following day, cells were transfected with 100 nm miR-141-3p mimic (UAAC ACUGUCUGGUAAAGAUGG), 100 nm miR-141-3p inhibitor (CCAUCUUUACCAGACAGUGUUA) or control. The MTT assay was used to measure cell proliferation with a microplate reader (BIO-RAD, Beijing, China).
hoechst 33258 assay
Hoechst 33258 assay was used to detect the effect of miR-141-3p on cell apoptosis. After transfection for 24 hours, cells were washed twice with PBS, incubated with 10 µg/mL Hoechst 33258 for 5 minutes at room temperature, and washed with PBS 3 times. Cells were observed with a fluorescence microscope.
annexin V (aV)-propidium iodide (Pi) assay AV-PI assay was used to detect the effect of miR-141-3p on cell apoptosis. The cells were washed twice with cold PBS, then resuspended with binding buffer at a concentration of 1×10 6 cells/mL. Then, 5 µL of ANNEXIN-V-fluorescein isothiocyanate and 10 µL of PI were added. The cells were incubated in the dark at room temperature for 15 minutes. Finally, 400 µL binding buffer was added to each tube, and the apoptosis rate was measured by flow cytometry within 1 hour.
Transwell Migration assay
Transwell was used to detect the effect of miR-141-3p on cell metastasis. After transfection, 1×10 5 cells in serum-free media were seeded in transwell chambers, and then a transwell assay 
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Results
The expression of egFr and mir-141-3p in osteosarcoma tissues
To detect the expression of EGFR in osteosarcoma, tumor tissues and adjacent normal tissues were obtained from 32 patients and analyzed by Western blot (17 paired) and RT-PCR (32 paired) ( Figure 1A and B). The results showed that the expression of EGFR in tumor tissues was higher than that in the adjacent tissues. At the same time, the expression of EGFR in osteosarcoma was detected by immunohistochemistry ( Figure 1C ). The results showed that EGFR was positively correlated with the GTM grade of osteosarcoma. Furthermore, the expression of miR-141-3p in osteosarcoma was detected by RT-PCR assay, which showed that the expression of miR-141-3p in osteosarcoma was low ( Figure 1D ). Patients with higher miR-141-3p expression had better prognosis than patients with low miR-141-3p expression ( Figure 1E ). We examined the correlation between miR-141-3p and osteosarcoma, and the results showed that miR-141-3p was associated with the classification of osteosarcoma (Table 1) . We found that the expression of miR-141-3p in osteosarcoma cell lines was low according to RT-PCR ( Figure 1F ). The expression of EGFR in MG63 and HOS cells was higher than that of hFOB1.19 cells ( Figure 1G and H).
mir-141-3p can inhibit the expression of egFr
The experiment showed that miR-141-3p can inhibit the expression of multiple proteins by using the miRDB tool (a site for miRNA target prediction and functional annotation of miRNA and target genes) ( Figure 2A ). Moreover, miR-141-3p can be targeted to the 3′-UTR region with EGFR ( Figure 2B ). We analyzed the results of the RT-PCR, and the expression of miR-141-3p was negatively correlated with the expression of EGFR in the osteosarcoma tissues ( Figure 2C ). The luciferase reporter assay was carried out to determine whether EGFR is a potential target gene of miR-141-3p ( Figure 2D ). The results showed that co-transfection of EGFR-WT with miR-141-3p produced lower luciferase activity in MG63 and HOS cells. However, no significant variation was observed in the cells co-transfected with EGFR-DEL or miR-141-3p AS. Western blot and RT-PCR were used to further validate the interaction of the miRNA-target ( Figure 2E -L). The results showed that the content of EGFR decreased when miR-141-3p was overexpressed in MG63 cells and that the miR-141-3p overexpression and low expression cell lines were successfully constructed. When miR-141-3p was inhibited in MG63 cells, the expression of EGFR was significantly increased.
mir-141-3p inhibits the proliferation of osteosarcoma cells
We examined the effects of different concentrations of miR-141 for MG63 and HOS cells. The results showed that the inhibitory effect of the transfection concentration of 100 nm on cells was obvious, and could be used for a follow-up experiment ( Figure 3A and B). MTT assays showed that the overexpression of miR-141-3p can inhibit the proliferation of osteosarcoma cells ( Figure 3C and D). Furthermore, the results showed that miR-141-3p can inhibit Akt p-Ser473 and cyclin D1 and thus played a role in inhibiting cell proliferation ( Figure 3E -H). The experimental results showed that miR-141-3p can affect the proliferation of cells by affecting the EGFR/Akt signaling pathway.
mir-141-3p promotes the apoptosis of osteosarcoma cells
The effect of miR-141-3p on the apoptosis of osteosarcoma cells was examined by Hoechst 33258 assay mir-141-3p inhibits the growth and migration of Mg63 cells EGFR and EGFR-DEL plasmid were transfected into overexpressed miR-141-3p cells. The MTT assay results confirmed that the inhibitory effect of miR-141-3p on MG63 was weakened after the loss of the specific miR-141-3p combining region in EGFR ( Figure 6A) . Then, the effect of miR-141-3p on apoptosis and metastasis was detected by Hoechst 33258, AV-PI, and transwell assays ( Figure 6B-D) . The results revealed that miR-141-3p could not promote cell apoptosis or inhibit migration by suppressing EGFR-DEL. Next, the inhibitory effect of miR-141-3p on the pathway was detected by Western blot and RT-PCR. The regulatory effect of miR-141-3p on EGFR downstream proteins was 
Discussion
As a kind of small, endogenous and noncoding RNA, miRNA can combine with the mRNA 3′-UTR, resulting in the inhibition of mRNA translation or the degradation of mRNA. 18 A large number of studies indicated that the abnormal expression of mRNA is closely related to the occurrence and development of many tumors. To date, many studies have reported that the abnormal expression of miRNA is involved in the occurrence and development of osteosarcoma. It is closely related to the prognosis of osteosarcoma. miR-141-3p is a member of the miR-200 family, which is thought to be abnormal in a variety of tumors. It can affect the biological function of the tumor cells by regulating the expression of proteins. miR-141-3p has been found to be highly expressed in various cancers, such as ovarian cancer, 19 colon cancer, 20 nasopharyngeal carcinoma, 11 prostate cancer, 21 gastric cancer, 22 and breast cancer. 23 Experiments showed that miR-141-3p can effectively predict the prognosis of HCC patients. The miR-141-3p/TAZ axis can inhibit the proliferation, migration, and invasion of gastric cancer cells. 24 The high expression of miR-141-3p was associated with a shorter overall survival of non-small cell lung cancer patients with adenocarcinoma through angiogenesis and mesenchymal epithelial transition factor. 25 miR-141-3p is upregulated in the serum of prostate cancer patients, and it may be a useful potential biomarker for the diagnosis of metastatic prostate cancer. 26 The present study indicates that the EGFR inhibitor ZD6474 has a certain effect on the treatment of osteosarcoma. 27 Another report showed that the anti-EGFR antibody cetuximab enhanced the cytolytic activity of natural killer cells toward osteosarcoma cells. 28 However, whether the expression of EGFR in osteosarcoma plays a significant role in the occurrence and development of osteosarcoma is still controversial. 
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In our study, we found that miR-141-3p was expressed at low levels in osteosarcoma, and there was a certain correlation between the expression of miR-141-3p and the survival rate of patients. At the same time, the expression of miR-141-3p was negatively correlated with the expression of EGFR. miR-141-3p can inhibit the expression of EGFR and the growth and migration of osteosarcoma by regulating the expression of EGFR.
In conclusion, our study showed that miR-141-3p can inhibit the occurrence and development of osteosarcoma by regulating the expression of EGFR. This suggests that miR-141-3p may play a specific role in the treatment of osteosarcoma. 
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